OncoMatch/Clinical Trials/NCT06563986
FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer
Is NCT06563986 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Systemic treatment (FTD-TPI and bevacizumab) and Radioembolization with 166-Ho microspheres for metastatic colorectal cancer.
Treatment: Systemic treatment (FTD-TPI and bevacizumab) · Radioembolization with 166-Ho microspheres — Extrahepatic disease progression limits clinical efficacy of individualized radioembolization for patients with refractory metastatic colorectal cancer (mCRC). In the same patient population, trifluridine/tipiracil (FTD-TPI) and bevacizumab lead to disease control and overall survival benefit and may be a radiosensitizer. The purpose of this study is to determine safety, tolerability, and activity of individualized radioembolization with 166Holmium (166Ho)-microspheres combined with FTD-TPI and bevacizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Unresectable liver dominant mCRC; At least one measurable liver lesion according to the PERCIST 1.0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluoropyrimidine — metastatic
Prior therapy with fluoropyrimidine for the treatment of metastatic colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
Must have received: oxaliplatin — metastatic
Prior therapy with oxaliplatin for the treatment of metastatic colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
Must have received: irinotecan — metastatic
Prior therapy with irinotecan for the treatment of metastatic colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen
Cannot have received: radioembolization
Previous or current treatment with radioembolization
Cannot have received: chemotherapy
Exception: within 28 days prior to study treatment
Receipt of chemotherapy within 28 days prior to study treatment
Lab requirements
Blood counts
WBC ≥ 3.0 x 10^9/L, platelets ≥ 100 x 10^9/L, absolute neutrophil count > 1.5 x 10^9/L, Hemoglobin (Hb) > 5 mmol/L (>8.1 g/dL)
Kidney function
eGFR ≥ 35 ml/min
Liver function
Serum transaminases (AST & ALT) ≤ 5 x upper limit of normal (ULN), Total bilirubin ≤ ULN, Albumin > 3 g/dL
Adequate organ function as measured by: WBC ≥ 3.0 x 10^9/L, platelets ≥ 100 x 10^9/L, absolute neutrophil count > 1.5 x 10^9/L, Hemoglobin (Hb) > 5 mmol/L (>8.1 g/dL), eGFR ≥ 35 ml/min, Serum transaminases (AST & ALT) ≤ 5 x upper limit of normal (ULN), Total bilirubin ≤ ULN, Albumin > 3 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify